Artiva Biotherapeutics develops AlloNK, a non-genetically modified, cryopreserved natural killer NK cell therapy designed for the treatment of autoimmune diseases and non-Hodgkin lymphoma. The company addresses the limitations of current cell therapies by providing a broadly accessible treatment option that reduces the complexities and costs associated with patient-specific manufacturing.
Funding
$120M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VHFounders
Product
Problem
Current cell therapies for autoimmune diseases and hematological malignancies often have severe toxicities and limited patient access due to complex, time-consuming, and costly patient-specific manufacturing processes. This makes these treatments available only to a small fraction of patients who could benefit.
Solution
Artiva Biotherapeutics is developing AlloNK, an allogeneic, non-genetically modified, cryopreserved natural killer (NK) cell therapy designed to overcome the limitations of patient-specific cell therapies. AlloNK aims to provide a broadly accessible, off-the-shelf treatment option that reduces the complexities and costs associated with current cell therapies. AlloNK is being evaluated as a monotherapy and in combination with monoclonal antibodies for the treatment of autoimmune diseases and in combination with innate cell engagers for the treatment of lymphomas.
Target Audience
The primary target audience includes patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and patients with hematological malignancies such as non-Hodgkin lymphoma, as well as the physicians treating these conditions.
Features
- Non-genetically modified NK cell therapy to minimize potential safety concerns
- Cryopreserved for off-the-shelf availability and simplified logistics
- Allogeneic cell source to enable large-scale manufacturing and broader patient access
- Designed for combination therapy with monoclonal antibodies and innate cell engagers
- Currently in clinical trials for systemic lupus erythematosus (SLE) and non-Hodgkin lymphoma